Cognition Therapeutics (NASDAQ:CGTX) Earns Buy Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $11.00 price target on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Cognition Therapeutics in a research note on Wednesday, November 27th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $8.30.

Cognition Therapeutics Trading Down 0.6 %

NASDAQ:CGTX opened at $0.63 on Thursday. The company has a market cap of $26.18 million, a P/E ratio of -0.65 and a beta of 1.26. Cognition Therapeutics has a twelve month low of $0.34 and a twelve month high of $2.95. The company’s 50-day moving average price is $0.48 and its 200-day moving average price is $0.92.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently made changes to their positions in CGTX. Virtu Financial LLC purchased a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at approximately $27,000. Sigma Planning Corp increased its stake in Cognition Therapeutics by 14.6% during the third quarter. Sigma Planning Corp now owns 197,190 shares of the company’s stock worth $92,000 after acquiring an additional 25,050 shares during the last quarter. CM Management LLC raised its position in Cognition Therapeutics by 14.3% in the second quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $332,000 after purchasing an additional 25,000 shares during the period. Finally, Mercer Global Advisors Inc. ADV lifted its stake in shares of Cognition Therapeutics by 33.4% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 95,951 shares of the company’s stock valued at $159,000 after purchasing an additional 24,050 shares during the last quarter. Hedge funds and other institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.